These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels. Um SW, Lee SW, Kwon SY, Yoon HI, Park KU, Song J, Lee CT, Lee JH. Int J Tuberc Lung Dis; 2007 Sep; 11(9):972-8. PubMed ID: 17705974 [Abstract] [Full Text] [Related]
11. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. Chest; 1998 May; 113(5):1178-83. PubMed ID: 9596291 [Abstract] [Full Text] [Related]
12. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring. Verbeeck RK, Günther G, Kibuule D, Hunter C, Rennie TW. Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904 [Abstract] [Full Text] [Related]
13. Comparative bioavailability of rifampicin and isoniazid in fixed-dose combinations and single-drug formulations. Hao LH, Guo SC, Liu CC, Zhu H, Wang B, Fu L, Chen MT, Zhou L, Chi JY, Yang W, Nie WJ, Lu Y. Int J Tuberc Lung Dis; 2014 Dec; 18(12):1505-12. PubMed ID: 25517820 [Abstract] [Full Text] [Related]
14. Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients. Kumar AKH, Chandrasekaran V, Kannan T, Lavanya J, Swaminathan S, Ramachandran G. Indian J Med Res; 2018 Mar; 147(3):287-292. PubMed ID: 29923518 [Abstract] [Full Text] [Related]
16. Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India. Hemanth Kumar AK, Kannan T, Chandrasekaran V, Sudha V, Vijayakumar A, Ramesh K, Lavanya J, Swaminathan S, Ramachandran G. Int J Tuberc Lung Dis; 2016 Sep; 20(9):1236-41. PubMed ID: 27510252 [Abstract] [Full Text] [Related]
17. Serum drug concentrations of INH and RMP predict 2-month sputum culture results in tuberculosis patients. Mah A, Kharrat H, Ahmed R, Gao Z, Der E, Hansen E, Long R, Kunimoto D, Cooper R. Int J Tuberc Lung Dis; 2015 Feb; 19(2):210-5. PubMed ID: 25574921 [Abstract] [Full Text] [Related]
18. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis]. Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H. Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568 [Abstract] [Full Text] [Related]
19. Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status. Ramachandran G, Kumar AK, Kannan T, Bhavani PK, Kumar SR, Gangadevi NP, Banurekha VV, Sudha V, Venkatesh S, Ravichandran N, Kalpana S, Mathevan G, Sanjeeva GN, Agarwal D, Swaminathan S. Pediatr Infect Dis J; 2016 May; 35(5):530-4. PubMed ID: 26825153 [Abstract] [Full Text] [Related]